Glenmark Life Science Share Price

Glenmark Life Science Share Price

NSE: ALIVUS
|
Pharmaceuticals
₹ 1,107.00
+₹4.20 (0.38%)
1D
Last updated 24 Jul, 2026, 15:29 IST

Glenmark Life Science Share Price Today

As of 25 Jul 2026, Glenmark Life Science share price is ₹1,107.00. The stock opened at ₹1,107.50, compared to its previous close of ₹1,102.80. During today's trading session, Glenmark Life Science share price moved in the range of ₹1,086.10 to ₹1,115.10, with an average price of ₹1,100.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹819.00 and a high of ₹1,193.90. On the performance front, Glenmark Life Science share price has increased by 24.64% over the last six months and is up 7.64% on a year-on-year basis.

₹1,086.10
0.38% up today
₹1,115.10
1D LOW
1D HIGH

Glenmark Life Science Returns Calculator

Circuit
L
H
₹881.00
₹1,321.40
52-week
L
H
₹819.00
₹1,193.90
Mkt Cap Cr
13,520.40
P/E
23.95
P/B
4.06
ROE
16.94%
D/E
0.02
ROCE
22.33%
Div. Yield
0.45%
EPS(TTM)
45.99
Turnover
0.73
EV/EBITDA
16.33
Net Margin
0.00%
Op. Margin
0.00%
ROA
14.17%
Quick Ratio
0.00
Curr. Ratio
5.30
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Alivus Life outperforming all market indices
Step 3 of 5
Valuation
Fairly Valued
Alivus Life appears to be fairly valued compared to its peers
Step 3 of 5
Earnings
Neutral
Alivus Life earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,65,711.0036.735.0514.85%0.5518.72%18.850.91%0.5610.90
Divis Laboratories1,93,860.0061.369.4016.19%0.0021.00%9.430.50%0.5898.19
Torrent Pharmaceuticals1,92,687.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,12,593.0033.553.2711.27%0.0014.95%423.360.93%0.4443.52
Zydus Lifesciences1,11,082.0017.393.2319.69%0.3520.30%3.700.11%0.3935.38
Lupin1,09,553.0019.834.7127.01%0.0327.44%3.510.78%0.61129.18
Mankind Pharma1,03,472.001.050.1212.65%0.4212.97%5.050.05%0.5449.37
Dr. Reddy's Laboratories96,204.7030.222.5311.07%0.1812.54%377.960.69%0.4138.68
Aurobindo Pharma88,508.4025.272.349.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs84,727.3060.2610.1018.21%0.4016.70%97.210.12%0.6413.72

Glenmark Life Science Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2019Mar 2020Mar 2021
Revenue886.861,549.31,885.98
Operating profit228.3421.07470.94
Net profit195.59313.1351.58

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹2,386.88₹2,283.21₹2,161.22₹2,123.21
Other Income₹34.57₹12.04₹28.96₹14.70
Total Revenue₹2,421.45₹2,295.26₹2,190.18₹2,137.92
Total Expenses₹1,767.32₹1,663.97₹1,561.57₹1,572.99
Profit Before Tax₹654.13₹631.29₹628.61₹564.93
Tax₹168.50₹160.40₹161.65₹146.20
Profit After Tax₹485.63₹470.89₹466.96₹418.72
EPS - Basic₹39.63₹38.43₹38.11₹35.63
EPS - Diluted₹39.52₹38.38₹38.11₹35.63

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹654.13₹631.29₹628.61₹564.93
Income before WC changes₹734.85₹710.56₹673.23₹635.91
Change in Assets-₹199.12-₹99.96-₹304.44₹26.09
Change in Liabilities₹18.75-₹34.12₹90.78₹73.75
Change in WC-₹180.38-₹134.08-₹213.66₹99.84
Cash flow from Operations₹391.52₹413.52₹306.01₹597.59
Cash flow from Investing-₹615.65-₹116.48-₹146.75-₹122.23
Cash flow from Financing-₹6.23-₹279.44-₹387.59-₹78.80
Total Cash Flow-₹230.35₹17.59-₹228.33₹396.56
Cash (Start of the year)₹301.41₹283.82₹512.16₹115.60
Cash (End of the year)₹71.06₹301.41₹283.82₹512.16

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹1,076.30₹934.41₹851.81₹706.42
Current Assets₹2,335.16₹1,916.00₹1,850.34₹1,764.58
Total Assets₹3,411.45₹2,850.41₹2,702.15₹2,471.01
Current Liabilities₹470.16₹438.77₹496.54₹384.00
Net Current Asset₹1,865.00₹1,477.23₹1,353.80₹1,380.59
Non-Current Liabilities₹123.92₹79.32₹67.40₹32.70
Equity Capital₹2,817.37₹2,332.32₹2,138.21₹2,054.31
Total Equity & Liabilities₹3,411.45₹2,850.41₹2,702.15₹2,471.01
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1101.2
3
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 3
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
3
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
43.84
Neutral
ATR (14)
33.61
Neutral
STOCH(9,6)
3.98
Bullish
STOCH RSI (14)
0
Bullish
ADX(9)
34.01
Bearish
UO(9)
34.52
Neutral
ROC(12)
-3.66
Bearish
WillR(14)
-96.1
Bullish
Period
Simple value
Exponential vaue
5D
1125.18
1122.07
10D
1141.29
1131.48
20D
1143.53
1129.1
50D
1091.07
1099.83
100D
1047.9
1057

About Glenmark Life Science

Glenmark Life Science Share Price
ISIN
INE03Q201024
Sector Market Cap
₹ 13,520.4 Cr

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.

Glenmark Life Science Financial Highlights

  • Revenue: Glenmark Life Science reported revenue of ₹1,885.98 crore in FY21 vs ₹1,549.30 crore in FY20. It showed an increase of 21.73% on a yearly basis.
  • Operating Profit: Glenmark Life Science reported an operating profit of ₹470.94 crore in FY21 vs ₹421.07 crore in FY20. It showed an increase of 11.84% on a year-on-year basis.
  • Net Profit: Glenmark Life Science reported a net profit of ₹351.58 crore in FY21 vs ₹313.10 crore in FY20. It showed an increase of 12.29% on a yearly basis.

Glenmark Life Science Quarterly Result Highlights

  • Glenmark Life Science reported revenue of ₹711.90 crore in Mar 2026, compared with ₹686.82 crore in Dec 2025, representing an increase of 3.65% on a quarter-on-quarter (QoQ) basis.
  • Glenmark Life Science reported an operating profit of ₹215.80 crore in Mar 2026, compared with ₹198.39 crore in Dec 2025, representing an increase of 8.78% on a quarter-on-quarter (QoQ) basis.
  • Glenmark Life Science reported a profit of ₹162.66 crore in Mar 2026, compared with ₹150.26 crore in Dec 2025, reflecting an increase of 8.25% on a QoQ basis.
  • The earnings per share (EPS) of Glenmark Life Science stood at ₹39.63 during Mar 2026.
Know more
Promoters
74.87%
FII
5.54%
Other DII
1.53%
Retail and other
12.41%
Mutual funds
5.65%
Foreign institutions - FII
Compare against other stocks
Glenmark Life Science Share Price
Glenmark Life Science
Pharmaceuticals
Add Stock
Add Another

FAQs on Glenmark Life Science Share Price